CD28 and melanoma: Moreover, compared to the co-stimulatory CAR-T domains DAP-10, CD28, 4-1BB, ICOS, and OX40, GITR co-stimulation exhibited stronger cytotoxicity in vivo in T cell lymphoma and melanoma models [18].